Jacob Van Naarden (Lilly Oncology)
Eli Lilly's Van Naarden hands $380M cash to Flagship-backed upstart in major new oncology deal
Jake Van Naarden, who rules the oncology roost at Eli Lilly, is back in the dealmaking game.
Monday morning he uncorked a deal to provide …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
